The market value of the global blood transfusion diagnostics was US$ 3,716.7 million in 2020. The market value of the global blood transfusion diagnostics is forecast to reach US$ 7311.3 million by 2030, growing at a compound annual growth rate (CAGR) of 7% during the forecast period from 2021-2030.
A blood transfusion occurs when one person gives blood to another or a blood component to another by infusing it into the vein. There are four components in blood: red blood cells, white blood cells, platelets, plasma, and clotting factors. Transferring blood requires checking for the presence of all the components. A transfusion can result in the transmission of infection and blood-borne diseases like post-transfusion purpura, anaphylactic reactions, delayed hemolytic reactions, and febrile non-hemolytic reactions.
Factors Influencing Market Growth
Impact Analysis of COVID-19
The COVID-19 outbreak has negatively impacted the market. In addition to reducing voluntary blood donations, the pandemic disrupted the supply chain for medical devices worldwide. During the crisis, blood banks and hospitals faced reduced donor inflows, staff shortages, shortages of blood units, and concerns about transfusion-transmitted COVID-19.
According to American Red Cross estimates, the organization lost around 46,000 blood units due to the pandemic. The lockdown and cancellation of blood drives resulted in a sharp decrease in blood donations at some donor centers.
All major blood centers saw an increase in donations and transfusion procedures across the board in the third quarter of 2020, as most of the major countries lifted lockdown and remain-at-home regulations. Thus, the global market will be able to experience an increase in growth.
Regional Insights
As of 2020, North America held the largest revenue share for blood transfusion diagnostics. It is forecast that the region will continue to grow during the forecast period. The growing awareness of health issues, a high disposable income, decent reimbursement policies, and an established healthcare infrastructure contribute to the market growth. Community Blood Center data indicates that nearly 43,000 pints of donated blood are used every day in both the U.S. and Canada.
The Asia Pacific is forecast to grow at the fastest rate during the forecast period for the blood transfusion diagnostics market. With the launch of various campaigns in India and Australia, awareness about blood donation is rising. In spite of this, decreasing number of donors in Singapore and South Korea has led to fewer adoptions of transfusion diagnostic tools in the Asia Pacific.
Leading Competitors
The leading prominent companies profiled in the global blood transfusion diagnostics market are:
Scope of the Report
The global blood transfusion diagnostics market segmentation focuses on Product, Application, End-use, and Region.
Segmentation based on Product
Segmentation based on Application
Segmentation based on End-use
Segmentation based on Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
4 GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE MODEL
4.4 VALUE CHAIN ANALYSIS
5 GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET, BY PRODUCT
5.1 OVERVIEW
5.2 REAGENTS & KITS
5.3 INSTRUMENTS
5.4 OTHERS
6 GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET, BY APPLICATION
6.1 OVERVIEW
6.2 BLOOD GROUPING
6.3 DISEASE SCREENING
6.3.1 SEROLOGICAL DISEASE SCREENING
6.3.2 MOLECULAR DISEASE SCREENING
7 GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET, BY END-USER
7.1 OVERVIEW
7.2 HOSPITALS
7.3 BLOOD BANKS
7.4 DIAGNOSTIC LABORATORIES
7.5 OTHERS
8 GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET, BY GEOGRAPHY
8.1 OVERVIEW
8.2 NORTH AMERICA
8.2.1 NORTH AMERICA MARKET SNAPSHOT
8.2.2 U.S.
8.2.3 CANADA
8.2.4 MEXICO
8.3 EUROPE
8.3.1 EUROPE MARKET SNAPSHOT
8.3.2 WESTERN EUROPE
8.3.2.1 THE UK
8.3.2.2 GERMANY
8.3.2.3 FRANCE
8.3.2.4 ITALY
8.3.2.5 SPAIN
8.3.2.6 REST OF WESTERN EUROPE
8.3.3 EASTERN EUROPE
8.3.3. 1 POLAND
8.3.3.2 RUSSIA
8.3.3.3 REST OF EASTERN EUROPE
8.4 ASIA PACIFIC
8.4.1 ASIA PACIFIC MARKET SNAPSHOT
8.4.2 CHINA
8.4.3 JAPAN
8.4.4 INDIA
8.4.5 AUSTRALIA & NEW ZEALAND
8.4.6 ASEAN
8.4.7 REST OF ASIA PACIFIC
8.5 MIDDLE EAST & AFRICA
8.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
8.5.2 UAE
8.5.3 SAUDI ARABIA
8.5.4 SOUTH AFRICA
8.5.5 REST OF MEA
8.6 SOUTH AMERICA
8.6.1 SOUTH AMERICA MARKET SNAPSHOT
8.6.2 BRAZIL
8.6.3 ARGENTINA
8.6.4 REST OF SOUTH AMERICA
9 GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPANY MARKET RANKING
9.3 KEY DEVELOPMENT STRATEGIES
10 COMPANY PROFILES
10.1 ABBOTT
10.1.1 OVERVIEW
10.1.2 FINANCIAL PERFORMANCE
10.1.3 PRODUCT OUTLOOK
10.1.4 KEY DEVELOPMENTS
10.2 BAG HEALTHCARE GMBH
10.2.1 OVERVIEW
10.2.2 FINANCIAL PERFORMANCE
10.2.3 PRODUCT OUTLOOK
10.2.4 KEY DEVELOPMENTS
10.3 BIOKIT (WERFEN)
10.3.1 OVERVIEW
10.3.2 FINANCIAL PERFORMANCE
10.3.3 PRODUCT OUTLOOK
10.3.4 KEY DEVELOPMENTS
10.4 BIO-RAD LABORATORIES
10.4.1 OVERVIEW
10.4.2 FINANCIAL PERFORMANCE
10.4.3 PRODUCT OUTLOOK
10.4.4 KEY DEVELOPMENTS
10.5 DANAHER
10.5.1 OVERVIEW
10.5.2 FINANCIAL PERFORMANCE
10.5.3 PRODUCT OUTLOOK
10.5.4 KEY DEVELOPMENTS
10.6 DIASORIN S.P.A.
10.6.1 OVERVIEW
10.6.2 FINANCIAL PERFORMANCE
10.6.3 PRODUCT OUTLOOK
10.6.4 KEY DEVELOPMENTS
10.7 F. HOFFMANN-LA ROCHE AG
10.7.1 OVERVIEW
10.7.2 FINANCIAL PERFORMANCE
10.7.3 PRODUCT OUTLOOK
10.7.4 KEY DEVELOPMENTS
10.8. IMMUCOR, INC.
10.8.1 OVERVIEW
10.8.2 FINANCIAL PERFORMANCE
10.8.3 PRODUCT OUTLOOK
10.8.4 KEY DEVELOPMENTS
10.9 ORTHO CLINICAL DIAGNOSTICS
10.9.1 OVERVIEW
10.9.2 FINANCIAL PERFORMANCE
10.9.3 PRODUCT OUTLOOK
10.9.4 KEY DEVELOPMENTS
10.10 QUOTIENT LIMITED
10.10.1 OVERVIEW
10.10.2 FINANCIAL PERFORMANCE
10.10.3 PRODUCT OUTLOOK
10.10.4 KEY DEVELOPMENTS
We Accept
Copyright ©2022 All rights reserved
